The long-awaited era of disease-modifying therapy for Alzheimer's disease has finally arrived and will substantially impact how the is perceived managed, although these new treatments pose challenges equitable access. drugs closest to widespread clinical implementation are lecanemab donanemab—intravenous monoclonal antibodies that remove β-amyloid plaques from brain can slow cognitive functiona...

The development of disease-modifying therapies for Alzheimer's disease (AD) is an urgent issue. Progress in the understanding of AD pathophysiology based on the amyloid hypothesis has led to the development of numerous candidate disease-modifying therapies over the past 15 years. The therapeutic target, amyloid β (Aβ), starts to accumulate in AD brains long before the onset of cognitive decline...

Disease modifying therapies are available for the treatment of relapse remitting multiple sclerosis, making relapses less common and severe. A Cochrane systematic review was undertaken to compare their benefit acceptability. This article summarises appraises evidence.